Skip to main content

Patent Litigation

Viewpoints

Filter by:

Intellectual Property Viewpoints Thumbnail
On June 26, 2020, the U.S. District Court for the District of Delaware, in VLSI Tech. LLC. v. Intel Corp, No. 18-0966-CFC, denied VLSI’s motion for leave to amend to add claims for willful infringement of U.S. Patent Nos. 6,212,633 (the “’633 patent”) and 7,523,331 (“the ’331 Patent”) based on pre-suit activity but granted it as to alleged post-suit infringement (which Intel did not oppose).
Read more
Intellectual Property Viewpoints Thumbnail

Shifting “Sands”: New Facts on the Ground Justify Institution of a Previously-Denied IPR

June 25, 2020 | Blog | By Michael Renaud, Adam Rizk, Daniel Weinger, Serge Subach

In a rare reversal, the Patent Trial and Appeal Board (“PTAB”) reassessed the Fintiv factors in a decision on a petition for rehearing of a previous decision denying institution of an inter partes review (“IPR”).  
Read more
Intellectual Property Viewpoints Thumbnail

The Federal Circuit Broadens Application of the Kessler Doctrine

June 23, 2020 | Blog | By Matthew Hurley, Philip C. Ducker, Adrian Kwan

Last week, the Federal Circuit invoked the Kessler doctrine in ruling that a district court’s dismissal of the plaintiff’s patent infringement suit against Amazon barred the plaintiff’s subsequent lawsuits against Amazon and its customers in In Re PersonalWeb Technologies, Inc.
Read more
Intellectual Property Viewpoints Thumbnail

No Fishing Allowed: Discovery of Litigation Funding Requires Articulation of Relevance Beyond Speculation

June 18, 2020 | Blog | By Michael Renaud, Andrew DeVoogd, Daniel Weinger, Catherine Xu

Read more
Intellectual Property Viewpoints Thumbnail

Arbitration of IP Disputes in a Post-COVID-19 World

June 2, 2020 | Blog | By Matthew Hurley, Michael Renaud, Nicholas Armington

The COVID-19 pandemic has caused individuals and companies alike to face the reality of a rapid economic downturn followed by a potentially slow recovery characterized by continued economic challenges.
Read more
Intellectual Property Viewpoints Thumbnail

Federal Circuit Appeals Continue as Scheduled Without In-Person Arguments

May 19, 2020 | Blog | By Brad M Scheller, Jessica Perry

Yesterday the United States Court of Appeals for the Federal Circuit released modifications to court procedures, indicating that all in-person oral arguments are suspended until further notice.
Read more
Intellectual Property Viewpoints Thumbnail

Federal Circuit Upholds Application of Dedication-Disclosure Doctrine at the Pleading Stage

May 15, 2020 | Blog | By Thomas Wintner, Adam Samansky, Nana Liu

On May 8, 2020, the Court of Appeals for the Federal Circuit affirmed the District of Delaware’s application of the disclosure-dedication doctrine in granting a motion for judgment on the pleadings in Eagle Pharmaceuticals Inc. v. Slayback Pharma LLC, No. 19-1924. 
Read more
Intellectual Property Viewpoints Thumbnail
After its recent ruling in Sisvel’s favor, Germany’s highest court on patent matters is expected to issue a highly favorable and detailed decision for standard-essential patent (SEP) owners seeking to prevent patent “hold-out” by unwilling licensees. 
Read more
Intellectual Property Viewpoints Thumbnail

Attorney Fees Denied by Federal Circuit Where Case Was Voluntarily Dismissed Without Prejudice

April 16, 2020 | Blog | By Daniel Weinger, Vincent Ferraro, Meena Seralathan

In an April 13, 2020, decision, the Federal Circuit held that neither a voluntary dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(i), nor a stay of a patent lawsuit pending the results of a patent reexamination, constitute a final judicial decision for the purposes of recovery of legal fees under 35 U.S.C. § 285. 
Read more
Intellectual Property Viewpoints Thumbnail
On Thursday, the Federal Circuit ruled that the Patent Trial and Appeal Board (“PTAB”) must give the parties proper notice if considering a sua sponte theory of unpatentability in relation to a motion to amend.
Read more
Intellectual Property Viewpoints Thumbnail

Celgene v. Sun Pharma Global: Satisfying Subject Matter Jurisdiction Under § 271(e)(2)

April 13, 2020 | Blog | By Adam Samansky, Peter Cuomo, Joe Rutkowski

On April 6, 2020, the U.S. District Court for the District of New Jersey, in Celgene Corp. v. Sun Pharma Global FZE, No. 19-cv-10099, denied Sun’s motion to dismiss Celgene’s claims that Sun’s generic Revlimid® (lenalidomide) Abbreviated New Drug Application (ANDA) product infringes three patents not listed in the Orange Book for Revlimid® and for which Sun did not make any Paragraph IV certifications.
Read more
Intellectual Property Viewpoints Thumbnail

Federal Circuit Denies En Banc Rehearing of Panel Decision in Arthrex, Which Held PTAB Appointments Were Unconstitutional

March 25, 2020 | Blog | By Daniel Weinger, Michael Newman, Vincent Ferraro, Matthew Galica

This week the en banc Federal Circuit declined to revisit a panel ruling that found the appointment of Administrative Patent Judges (“APJs”) of the Patent Trial and Appeal Board (“PTAB”) violates the Appointments Clause of the Constitution.  This decision is notable for at least two reasons. First, it declined to review or disturb the panel’s conclusion and its remedy—vacatur and remand of PTAB decisions made by unconstitutionally appointed APJs. Second, four of the Federal Circuit judges dissented, disagreeing with the panel’s finding and saying that its corresponding remedy improperly rewrites the statute contrary to Congressional intent.
Read more
Intellectual Property Viewpoints Thumbnail
The Court of Appeals for the Federal Circuit ruled in February that the Patent Trial and Appeal Board (PTAB) cannot cancel claims for indefiniteness in an inter partes review (IPR) proceeding. The case is Samsung Electronics America, Inc., v. Prisua Engineering Corp., case number 19-1169, in the U.S. Court of Appeals for the Federal Circuit.
Read more
Intellectual Property Viewpoints Thumbnail
In a February 19, 2020 decision the Federal Circuit held that a patentee does not escape 35 U.S.C. § 287’s marking requirement merely by ceasing sales of the practicing product.  Instead, the Federal Circuit held that once a patentee (or its licensees) sell articles that practice the patent, the obligation to mark in order to obtain pre-suit damages continues regardless of whether sales of the product in question cease. 
Read more
Intellectual Property Viewpoints Thumbnail

Infringement Contentions: Fair Notice?

February 18, 2020 | Blog | By Michael Renaud, Adam Rizk, Catherine Xu

Some respondents at the ITC have taken advantage of using infringement contentions as a procedural tool to deny patent owners from getting their day in court.  In some investigations, respondents have gone so far as to delay their own production of discovery until after the infringement contention deadline, then claim lack of fair notice when the patent owner uses the late discovery in its expert report.
Read more
Intellectual Property Viewpoints Thumbnail
The Federal Circuit affirmed a district court award of over $360,000 in costs and attorneys’ fees against a non-practicing entity, citing the need “to deter future abusive litigation.”
Read more
Intellectual Property Viewpoints Thumbnail
Mintz is recognized as among the top ten firms in ITC Section 337 litigation by Patexia in its inaugural "ITC Intelligence Report". We are pleased to be among the firms included in this publication and thrilled that it has come on the heels of a great year at the ITC for the Mintz team.
Read more
Viewpoint Thumbnail
On December 18, 2019, the United States Court of Appeals for the Federal Circuit, in Fox Factory v. SRAM, Nos. 2018-2024 and 2018-2025, reversed the Board’s Final Written Decision in a pair of inter partes reviews (“IPRs”) that the challenged claims of U.S. Patent No. 9,182,027 (“the ’027 patent”) were not invalid as obvious, and remanded for further proceedings.
Read more
Viewpoint Thumbnail
When licensing discussions with an intransigent implementer break down, SEP owners face a difficult question: what remedies are available (injunctive relief or damages) in each U.S. court (International Trade Commission and U.S. district courts) as redress against infringement?
Read more
Viewpoint Thumbnail

Federal Circuit affirms Safe Harbor ruling and $70 million award in Amgen Inc. v. Hospira, Inc.

December 20, 2019 | Blog | By Thomas Wintner, Peter Cuomo, Nana Liu

On December 16, 2019, the Court of Appeals for the Federal Circuit issued an opinion that fully upheld the District of Delaware’s denial of Hospira, Inc.’s motion for judgment as a matter of law (JMOL), or alternative motion for new trial, in Amgen Inc. v. Hospira, Inc., Nos. 2019-1067, 2019-1102.  
Read more
Sign up to receive email updates from Mintz.
Subscribe Now

Explore Other Viewpoints: